We are pleased to announce that Mindray has recently reached an equity transfer agreement with Suzhou Hyssen Electronics Co., Ltd. (“Hyssen”), through which Mindray will acquire a controlling stake in Hyssen.
Under the agreement, Mindray will gain access to Hyssen’s urine sediment analysis products, as well as its research and development capabilities. Hyssen’s products complement Mindray’s current in-vitro diagnostic product offerings in urine dry chemistry, hematology and biochemistry. With the new additions, Mindray’s in-vitro diagnostic segment can now provide their customers with better and more complete solutions.
Mindray will utilize its strong platforms in manufacturing, research and development, quality assurance, sales and marketing to support Hyssen’s future development. We aim to work diligently with Hyssen to help strengthen the company’s leading position in urine sediment analysis in China.
We believe that the collaboration between Mindray and Hyssen will bring many synergies to both parties. We expect that our combined efforts will provide better products and services to our customers, broader development opportunities to our employees, and help Hyssen establish a stronger position to compete in the market place.
About Hyssen:
Located in China-Singapore Suzhou Industrial Park, Hyssen is a developer, manufacturer and marketer of automated urine sediment analyzers. Please refer to www.hyssen.cn for more information.
Shenzhen Mindray Biomedical Electronics Co., Ltd.
July 08, 2011